Sales & Marketing

Sales & Marketing

The latest pharmaceutical sales and marketing news

Treatment programme for CVD to be developed as part of partnership between Novartis and IonisTreatment programme for CVD to be developed as part of partnership between Novartis and Ionis
Treatment programme for CVD to be developed as part of partnership between Novartis and Ionis

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and licence agreement with Novartis, aiming to discover, develop and commercialise a novel medicine for patients with lipoprotein(a) or lp(a)-driven cardiovascular disease (CVD).

Aug 24, 2023 Sales & Marketing
Biogen plans to acquire Reata Pharmaceuticals for $7.3bnBiogen plans to acquire Reata Pharmaceuticals for $7.3bn
Biogen plans to acquire Reata Pharmaceuticals for $7.3bn

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for approximately $7.3bn, or $172.50 per share.

Aug 24, 2023 Sales & Marketing
Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s AlexionRare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion
Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion

Alexion has announced that it has entered a definitive purchase and licence agreement with Pfizer.

Aug 24, 2023 Sales & Marketing
Eli Lilly shares plans to acquire Versanis Bio for $1.9bnEli Lilly shares plans to acquire Versanis Bio for $1.9bn
Eli Lilly shares plans to acquire Versanis Bio for $1.9bn

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focusing on the development of new medicines to treat cardiometabolic diseases.

Aug 24, 2023 Sales & Marketing
LaNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADCLaNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC
LaNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC

Chinese biotechnology company LaNova medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive licence agreement for a preclinical stage antibody drug conjugate (ADC).

Jul 2, 2023 Sales & Marketing
Lonza to acquire Synaffix to strengthen ADC developmentLonza to acquire Synaffix to strengthen ADC development
Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza, has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

Jul 2, 2023 Sales & Marketing
Gilead acquires XinThera to strengthen pipeline in oncology and inflammationGilead acquires XinThera to strengthen pipeline in oncology and inflammation
Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead sciences has announced the acquisition of all outstanding shares of XinThera, a privately owned biotech company based in San Diego, US. This acquisition aims to strengthen Gilead’s clinical development pipeline through the addition of XinThera’s oncology and inflammation assets.

May 25, 2023 Sales & Marketing
GSK enters into £1.6bn deal to acquire Bellus HealthGSK enters into £1.6bn deal to acquire Bellus Health
GSK enters into £1.6bn deal to acquire Bellus Health

UK-based GSK has announced its plans to acquire Bellus Health, a Canadian late-stage biopharmaceutical company that focuses on treatments for refractory chronic cough (RCC). The acquisition will give GSK access to Camlipixant, Bellus’ first-in-class treatment for RCC.

May 25, 2023 Sales & Marketing
Sobi acquires CTI BioPharma Corporation for $1.7bnSobi acquires CTI BioPharma Corporation for $1.7bn
Sobi acquires CTI BioPharma Corporation for $1.7bn

Swedish Orphan Biovitrum (Sobi) has announced that it had entered into a ‘plan of merger’ with CTI Biopharma Corp (CTI), a biopharmaceutical company focused on blood-related cancers and rare diseases, by means of a tender offer valued at $1.7bn.

May 25, 2023 Sales & Marketing
BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibodyBioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody
BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody

BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple solid tumour indications. BioNTech will receive an exclusive worldwide license from oncoc4 for its anti-ctla-4 monoclonal antibody candidate, onc-392.

Apr 30, 2023 Sales & Marketing
Pfizer signs $43bn deal to buy SeagenPfizer signs $43bn deal to buy Seagen
Pfizer signs $43bn deal to buy Seagen

Pharma giant Pfizer has signed a definitive merger agreement valued at $43bn to buy biotech firm Seagen. US-based Seagen discovers, develops and commercialises cancer medicines through pioneering antibody-drug conjugates (ADCs) technology. It currently has four approved medicines in its portfolio, including three ADCs: adcetris (brentuximab vedotin) for lymphoma; padcev (enfortumab vedotin) for bladder cancers; and tivdak (tisotumab vedotin) for cervical cancer.

Apr 30, 2023 Sales & Marketing
Théa Open Innovation & Galimedix announce partnership for development & commercialisation of GAL-101Théa Open Innovation & Galimedix announce partnership for development & commercialisation of GAL-101
Théa Open Innovation & Galimedix announce partnership for development & commercialisation of GAL-101

Théa Open Innovation (TOI) and Galimedix have announced that they have signed a licensing agreement granting TOI exclusive rights for the development and commercialisation of GAL-101, Galimedix’s treatment for dry age-related macular degeneration (AMD), glaucoma and other ophthalmic indications with high unmet medical need, in Europe, the Americas, the Middle East and Africa.

Apr 30, 2023 Sales & Marketing